Evidence map›Paper›PMID 23489141›Full record

ArticleBritish journal of pharmacology2013

PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.

Peter Molenaar, Torsten Christ, Rizwan I Hussain, Andreas Engel, Emanuel Berk, Katherine T Gillette, Lu Chen, Alejandro Galindo-Tovar, Kurt A Krobert, Ursula Ravens and 2 more

Open access · greenAbstract read
In one paragraph

Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 55 citations in OpenAlex.

  1. βNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. Bromopride stimulates 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Progress in Bioengineering Strategies for Heart Regenerative Medicine.International journal of molecular sciences · 2022
    Review
  11. Review
  12. The Role of POPDC Proteins in Cardiac Pacemaking and Conduction.Journal of cardiovascular development and disease · 2021
    Review
  13. Compartmentation of βBritish journal of pharmacology · 2021
    Article
  14. Regulation of IBritish journal of pharmacology · 2020
    Article
  15. Treatments targeting inotropy.European heart journal · 2019
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Peter MolenaarFaculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
Torsten Christ
Rizwan I Hussain
Andreas Engel
Emanuel Berk
Katherine T Gillette
Lu Chen
Alejandro Galindo-Tovar
Kurt A Krobert
Ursula Ravens
Finn Olav Levy
Alberto J Kaumann
TU Dresden · DEOslo University Hospital · NOPrince Charles Hospital · AUHospital Universitario Virgen de la Arrixaca · ESUniversity of Cambridge · GBUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposePDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle are unknown. We investigated whether the PDE3-selective inhibitor cilostamide (0.3-1 μM) or PDE4 inhibitor rolipram (1-10 μM) modified the positive inotropic and lusitropic effects of catecholamines in human failing myocardium. EXPERIMENTAL APPROACH: Right and left ventricular trabeculae from freshly explanted hearts of 5 non-β-blocker-treated and 15 metoprolol-treated patients with terminal heart failure were paced to contract at 1 Hz. The effects of (-)-noradrenaline, mediated through β₁ adrenoceptors (β₂ adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through β₂ adrenoceptors (β₁ adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of PDE inhibitors. Catecholamine potencies were estimated from -logEC₅₀s. KEY

resultsCilostamide did not significantly potentiate the inotropic effects of the catecholamines in non-β-blocker-treated patients. Cilostamide caused greater potentiation (P = 0.037) of the positive inotropic effects of (-)-adrenaline (0.78 ± 0.12 log units) than (-)-noradrenaline (0.47 ± 0.12 log units) in metoprolol-treated patients. Lusitropic effects of the catecholamines were also potentiated by cilostamide. Rolipram did not affect the inotropic and lusitropic potencies of (-)-noradrenaline or (-)-adrenaline on right and left ventricular trabeculae from metoprolol-treated patients. CONCLUSIONS AND IMPLICATIONS: Metoprolol induces a control by PDE3 of ventricular effects mediated through both β₁ and β₂ adrenoceptors, thereby further reducing sympathetic cardiostimulation in patients with terminal heart failure. Concurrent therapy with a PDE3 blocker and metoprolol could conceivably facilitate cardiostimulation evoked by adrenaline through β₂ adrenoceptors. PDE4 does not appear to reduce inotropic and lusitropic effects of catecholamines in failing human ventricle.

Indexed as

Adrenergic alpha-AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AntagonistsAdrenergic beta-AgonistsAnti-Arrhythmia AgentsCardiotonic AgentsCyclic Nucleotide Phosphodiesterases, Type 3Cyclic Nucleotide Phosphodiesterases, Type 4Drug ResistanceEpinephrineHeart FailureHeart TransplantationHeart VentriclesHumansIn Vitro TechniquesMetoprololADRB1 protein, humanADRB2 protein, humanAdrenergic alpha-AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AntagonistsAdrenergic beta-AgonistsAnti-Arrhythmia AgentsCardiotonic AgentsCyclic Nucleotide Phosphodiesterases, Type 3Cyclic Nucleotide Phosphodiesterases, Type 4EpinephrineMetoprololNorepinephrinePDE3A protein, humanPDE4A protein, humanPhosphodiesterase 3 InhibitorsPhosphodiesterase 4 InhibitorsReceptors, Adrenergic, beta-1Receptors, Adrenergic, beta-2

Identifiers

PMID23489141
PMCPMC3682702
OpenAlexW1545935022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.